A Divergent Role for Estrogen Receptor-beta in Node-positive and Node-negative Breast Cancer Classified According to Molecular Subtypes: an Observational Prospective Study

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2008 Sep 6

PMID 18771580

Citations 49

Authors

Flavia Novelli

Michele Milella

Elisa Melucci

Anna Di Benedetto

Isabella Sperduti

Raffaele Perrone-Donnorso

Letizia Perracchio

Irene Venturo

Cecilia Nistico

Alessandra Fabi

Simonetta Buglioni

Pier Giorgio Natali

Marcella Mottolese

Affiliations

Soon will be listed here.

Abstract

Introduction: Estrogen receptor-alpha (ER-alpha) and progesterone receptor (PgR) are consolidated predictors of response to hormonal therapy (HT). In contrast, little information regarding the role of estrogen receptor-beta (ER-beta) in various breast cancer risk groups treated with different therapeutic regimens is available. In particular, there are no data concerning ER-beta distribution within the novel molecular breast cancer subtypes luminal A (LA) and luminal B (LB), HER2 (HS), and triple-negative (TN).

Methods: We conducted an observational prospective study using immunohistochemistry to evaluate ER-beta expression in 936 breast carcinomas. Associations with conventional biopathological factors and with molecular subtypes were analyzed by multiple correspondence analysis (MCA), while univariate and multivariate Cox regression analysis and classification and regression tree analysis were applied to determine the impact of ER-beta on disease-free survival in the 728 patients with complete follow-up data.

Results: ER-beta evenly distributes (55.5%) across the four molecular breast cancer subtypes, confirming the lack of correlation between ER-beta and classical prognosticators. However, the relationships among the biopathological factors, analyzed by MCA, showed that ER-beta positivity is located in the quadrant containing more aggressive phenotypes such as HER2 and TN or ER-alpha/PgR/Bcl2- tumors. Kaplan-Meier curves and Cox regression analysis identified ER-beta as a significant discriminating factor for disease-free survival both in the node-negative LA (P = 0.02) subgroup, where it is predictive of response to HT, and in the node-positive LB (P = 0.04) group, where, in association with PgR negativity, it conveys a higher risk of relapse.

Conclusion: Our data indicated that, in contrast to node-negative patients, in node-positive breast cancer patients, ER-beta positivity appears to be a biomarker related to a more aggressive clinical course. In this context, further investigations are necessary to better assess the role of the different ER-beta isoforms.

Citing Articles

Metabolomics integrated genomics approach: Understanding multidrug resistance phenotype in MCF-7 breast cancer cells exposed to doxorubicin and ABCA1/EGFR/PI3k/PTEN crosstalk.

Kadry M, Abd-Ellatef G, Ammar N, Hassan H, Hussein N, Kamel N Toxicol Rep. 2025; 14:101884.

PMID: 39886047 PMC: 11780168. DOI: 10.1016/j.toxrep.2024.101884.

Titanium dioxide nanostructure-loaded Adriamycin surmounts resistance in breast cancer therapy: ABCA/P53/C-myc crosstalk.

Abdel-Megeed R, Abdel-Hamid A, Kadry M Future Sci OA. 2024; 10(1):FSO979.

PMID: 38827789 PMC: 11140649. DOI: 10.2144/fsoa-2023-0107.

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches.

Pastena P, Perera H, Martinino A, Kartsonis W, Giovinazzo F Int J Mol Sci. 2024; 25(5).

PMID: 38473804 PMC: 10931553. DOI: 10.3390/ijms25052559.

The Potential of Hormonal Therapies for Treatment of Triple-Negative Breast Cancer.

Kirkby M, Popatia A, Lavoie J, Wang L Cancers (Basel). 2023; 15(19).

PMID: 37835396 PMC: 10571841. DOI: 10.3390/cancers15194702.

Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.

Ahluwalia P, Vashisht A, Singh H, Sahajpal N, Mondal A, Jones K J Med Virol. 2023; 95(9):e29067.

PMID: 37675796 PMC: 10536788. DOI: 10.1002/jmv.29067.

References

Murphy L, Watson P . Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomed Pharmacother. 2002; 56(2):65-77. DOI: 10.1016/s0753-3322(01)00157-3. View

Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F . ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology. 2001; 142(9):4120-30. PMC: 2040491. DOI: 10.1210/endo.142.9.8395. View

Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M . Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett. 2001; 163(2):207-12. DOI: 10.1016/s0304-3835(00)00680-7. View

Skliris G, Parkes A, Limer J, Burdall S, Carder P, Speirs V . Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol. 2002; 197(2):155-62. DOI: 10.1002/path.1077. View

Knowlden J, Gee J, Robertson J, Ellis I, Nicholson R . A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. Int J Cancer. 2001; 89(2):209-12. DOI: 10.1002/(sici)1097-0215(20000320)89:2<209::aid-ijc17>3.0.co;2-6. View

Gruvberger-Saal S, Bendahl P, Saal L, Laakso M, Hegardt C, Eden P . Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res. 2007; 13(7):1987-94. DOI: 10.1158/1078-0432.CCR-06-1823. View

Yang X, Pfeiffer R, Garcia-Closas M, Rimm D, Lissowska J, Brinton L . Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res. 2007; 67(21):10608-17. DOI: 10.1158/0008-5472.CAN-07-2142. View

Horvath L, Henshall S, Lee C, Head D, Quinn D, Makela S . Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 2001; 61(14):5331-5. View

Lemon S, Roy J, Clark M, Friedmann P, Rakowski W . Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med. 2003; 26(3):172-81. DOI: 10.1207/S15324796ABM2603_02. View

10.

Hopp T, Weiss H, Parra I, Cui Y, Osborne C, Fuqua S . Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004; 10(22):7490-9. DOI: 10.1158/1078-0432.CCR-04-1114. View

11.

Ambrogi F, Biganzoli E, Querzoli P, Ferretti S, Boracchi P, Alberti S . Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods. Clin Cancer Res. 2006; 12(3 Pt 1):781-90. DOI: 10.1158/1078-0432.CCR-05-0763. View

12.

Platet N, Cathiard A, Gleizes M, Garcia M . Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol. 2004; 51(1):55-67. DOI: 10.1016/j.critrevonc.2004.02.001. View

13.

Speirs V, Malone C, Walton D, Kerin M, Atkin S . Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999; 59(21):5421-4. View

14.

Jarvinen T, Pelto-Huikko M, Holli K, Isola J . Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 2000; 156(1):29-35. PMC: 1868617. DOI: 10.1016/s0002-9440(10)64702-5. View

15.

Buzdar A . Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Breast Dis. 2006; 24:107-17. DOI: 10.3233/bd-2006-24109. View

16.

Folgiero V, Avetrani P, Bon G, Di Carlo S, Fabi A, Nistico C . Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. PLoS One. 2008; 3(2):e1592. PMC: 2220038. DOI: 10.1371/journal.pone.0001592. View

17.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

18.

Skliris G, Leygue E, Watson P, Murphy L . Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol. 2008; 109(1-2):1-10. DOI: 10.1016/j.jsbmb.2007.12.010. View

19.

Buglioni S, DAgnano I, Cosimelli M, Vasselli S, DAngelo C, Tedesco M . Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer. 1999; 84(6):545-52. DOI: 10.1002/(sici)1097-0215(19991222)84:6<545::aid-ijc1>3.0.co;2-2. View

20.

Paech K, Webb P, Kuiper G, Nilsson S, Gustafsson J, Kushner P . Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science. 1997; 277(5331):1508-10. DOI: 10.1126/science.277.5331.1508. View